Keywords: Pfizer, China, Japan, Generics,

Pfizer to be biggest beneficiary of China pharma market, say Goldman Sachs analysts; firm also set for Japanese generics market

Article | 24 November 2009

• Print This

The world’s largest drugmaker, USA-based Pfizer, is eyeing the Japanese generics market and, in an investment review of the company, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company's revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer.

Reported by numerous news sources, Goldman expects emerging growth markets to produce $3.5 billion of revenue for Pfizer in 2012, of which $3 billion of will come from China. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.